Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CG-BM1 for Acute-on-chronic Liver Failure
NCT06740149Phase 2Completed
- Sponsor
- Guangzhou Saijun Biotechnology Co., Ltd.
- Start
- Mar 2023
- Primary completion
- Mar 2026
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of bone marrow mesenchymal stem cells in acute-on-chronic liver failure (ACLF), sponsored by Guangzhou Saijun Biotechnology Co., Ltd.. Started Mar 2023; status: completed.
02
Drugs
bone marrow mesenchymal stem cells
03
Conditions
acute-on-chronic liver failure (ACLF)
Beyond the preview
Go deeper on NCT06740149.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06740149.